🇺🇸 FDA
Patent

US 10233172

Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

granted A61PA61P1/00A61P1/04

Quick answer

US patent 10233172 (Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/10, A61P1/14